360 related articles for article (PubMed ID: 22427684)
1. Changing concepts: Menopausal hormone therapy and breast cancer.
Chlebowski RT; Anderson GL
J Natl Cancer Inst; 2012 Apr; 104(7):517-27. PubMed ID: 22427684
[TBL] [Abstract][Full Text] [Related]
2. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
Chlebowski RT; Manson JE; Anderson GL; Cauley JA; Aragaki AK; Stefanick ML; Lane DS; Johnson KC; Wactawski-Wende J; Chen C; Qi L; Yasmeen S; Newcomb PA; Prentice RL
J Natl Cancer Inst; 2013 Apr; 105(8):526-35. PubMed ID: 23543779
[TBL] [Abstract][Full Text] [Related]
3. The Women's Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context.
Chlebowski RT; Aragaki AK
Menopause; 2023 Apr; 30(4):454-461. PubMed ID: 36727752
[TBL] [Abstract][Full Text] [Related]
4. Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.
Chlebowski RT; Anderson GL
Steroids; 2014 Nov; 90():53-9. PubMed ID: 24910928
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index.
Chlebowski RT; Anderson GL; Aragaki AK; Prentice R
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26546117
[TBL] [Abstract][Full Text] [Related]
6. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes.
Harman SM; Vittinghoff E; Brinton EA; Budoff MJ; Cedars MI; Lobo RA; Merriam GR; Miller VM; Naftolin F; Pal L; Santoro N; Taylor HS; Black DM
Am J Med; 2011 Mar; 124(3):199-205. PubMed ID: 21396500
[TBL] [Abstract][Full Text] [Related]
7. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
Simon JA; Nahum GG; Stanislaw H; Gaines T
Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
[TBL] [Abstract][Full Text] [Related]
8. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.
Chlebowski RT; Hendrix SL; Langer RD; Stefanick ML; Gass M; Lane D; Rodabough RJ; Gilligan MA; Cyr MG; Thomson CA; Khandekar J; Petrovitch H; McTiernan A;
JAMA; 2003 Jun; 289(24):3243-53. PubMed ID: 12824205
[TBL] [Abstract][Full Text] [Related]
9. Reliable evidence from placebo-controlled, randomized, clinical trials for menopausal hormone therapy's influence on incidence and deaths from breast cancer.
Chlebowski RT; Anderson GL; Prentice RL; Rossouw JE; Aragaki AK; Manson JE
Climacteric; 2015 Jun; 18(3):336-8. PubMed ID: 25966858
[TBL] [Abstract][Full Text] [Related]
10. Estrogen plus progestin and risk of benign proliferative breast disease.
Rohan TE; Negassa A; Chlebowski RT; Lasser NL; McTiernan A; Schenken RS; Ginsberg M; Wassertheil-Smoller S; Page DL
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2337-43. PubMed ID: 18725513
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Rohan TE; Manson JE; Aragaki AK; Kaunitz A; Stefanick ML; Simon MS; Johnson KC; Wactawski-Wende J; O'Sullivan MJ; Adams-Campbell LL; Nassir R; Lessin LS; Prentice RL
JAMA Oncol; 2015 Jun; 1(3):296-305. PubMed ID: 26181174
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer after use of estrogen plus progestin in postmenopausal women.
Chlebowski RT; Kuller LH; Prentice RL; Stefanick ML; Manson JE; Gass M; Aragaki AK; Ockene JK; Lane DS; Sarto GE; Rajkovic A; Schenken R; Hendrix SL; Ravdin PM; Rohan TE; Yasmeen S; Anderson G;
N Engl J Med; 2009 Feb; 360(6):573-87. PubMed ID: 19196674
[TBL] [Abstract][Full Text] [Related]
13. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
14. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
Speroff L
Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer risk in relation to the interval between menopause and starting hormone therapy.
Beral V; Reeves G; Bull D; Green J;
J Natl Cancer Inst; 2011 Feb; 103(4):296-305. PubMed ID: 21278356
[TBL] [Abstract][Full Text] [Related]
16. Menopausal hormone therapy and breast cancer.
Santen RJ
J Steroid Biochem Mol Biol; 2014 Jul; 142():52-61. PubMed ID: 23871991
[TBL] [Abstract][Full Text] [Related]
17. Re: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Kuller LH
J Natl Cancer Inst; 2000 Jul; 92(13):1100-1. PubMed ID: 10880556
[No Abstract] [Full Text] [Related]
18. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
[TBL] [Abstract][Full Text] [Related]
19. Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?
Falk RT; Manson JE; Barnabei VM; Anderson GL; Brinton LA; Rohan TE; Cauley JA; Chen C; Coburn SB; Pfeiffer RM; Reding KW; Sarto GE; Wentzensen N; Chlebowski RT; Xu X; Trabert B
Int J Cancer; 2019 Feb; 144(4):730-740. PubMed ID: 30183089
[TBL] [Abstract][Full Text] [Related]
20. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
Nozaki M; Koera K; Nagata H; Nakano H
J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
